**4. Lessons from RTK-targeted therapies**

Since the phase III trials of Temozolomide in 2005, there have been few successes regarding treatment for patients with malignant glioma [82]. RTKs, which are the most commonly amplified and mutated genes in cancers, are the key targets in cancer research including malignant glioma. Up to date, three RTKs and their family members present the major druggable targets, including EGFR and EGFRvIII, VEGFR and PDGFR family.
